p53 haploinsufficiency and functional abnormalities in multiple myeloma. (Q39015919)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

p53 haploinsufficiency and functional abnormalities in multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

P J Teoh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

T H Chung

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

S Sebastian

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

S N Choo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

J Yan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

R Fonseca

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

W J Chng

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

14 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

2066-2074

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Live or let die: the cell's response to p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Clinical significance of TP53 mutation in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Clinical and biologic implications of recurrent genomic aberrations in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Initial genome sequencing and analysis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

NCBI GEO: archive for functional genomics data sets--update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

NCBI Reference Sequences (RefSeq): current status, new features and genome annotation policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Methylation in the p53 promoter in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

The molecular classification of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

The role of mutant p53 in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

A common gain of function of p53 cancer mutants in inducing genetic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Pharmacological activation of the p53 pathway in haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

A gene expression signature for high-risk multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Targeting the MDM2-p53 interaction for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Links between mutant p53 and genomic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Thymocyte apoptosis induced by p53-dependent and independent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Methylation status of nine tumor suppressor genes in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Methylation profiling in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.102

The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy

21 January 2018

1 reference

12 December 2020

Fluorescent in situ hybridization studies in multiple myeloma

1 reference

12 December 2020

Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A

1 reference

12 December 2020

p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase

1 reference

12 December 2020

MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells

1 reference

12 December 2020

Murine double minute 2 and its association with chemoradioresistance of esophageal squamous cell carcinoma

1 reference

12 December 2020

MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity

1 reference

12 December 2020

Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.

1 reference

12 December 2020

DNA methylation changes in multiple myeloma

1 reference

12 December 2020

Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions

1 reference

12 December 2020

p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2014.102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24625551%20AND%20SRC:MED&resulttype=core&format=json